公开(公告)号：US20180282728A1

公开(公告)日：2018-10-04

申请号：US16007517

申请日：2018-06-13

申请人： Arrowhead Pharmaceuticals, Inc.

发明人： Brian Richard Bettencourt ,  David Anton Bumcrot ,  Dieter Huesken ,  Satyanarayana Kuchimanchi ,  Stuart Milstein ,  Michael Ray Schlabach, JR. ,  Frank Peter Stegmeier ,  Markus Warmuth ,  Jan Weiler

IPC分类号： C12N15/113 ,  A61K31/713

摘要： The present disclosure relates to RNAi agents useful in methods of treating Beta-Catenin-related diseases such as adenomatous polyposis of the colon, colorectal cancer, basal cell carcinoma, breast cancer, kidney cancer, Wilms tumors, medulloblastoma, ovarian cancer, adrenocortical tumors, gastric cancer, liver cancer, melanoma, pancreatic cancers, prostate cancer, renal cancer, ectopic teeth and taste papillae, skin cancer, pilomatrixoma, anaplastic thyroid carcinoma, and uterine carcinosarcoma, oligodontia, osteoporosis, ageing, degenerative diseases, bedsores, chronic wounds and impaired wound healing, and similar and related diseases, using a therapeutically effective amount of a RNAi agent to Beta-Catenin.